News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
559,014 Results
Type
Article (45046)
Company Profile (145)
Press Release (513823)
Section
Business (158758)
Career Advice (2436)
Deals (29904)
Drug Delivery (105)
Drug Development (72670)
Employer Resources (151)
FDA (16110)
Job Trends (12544)
News (285219)
Policy (31037)
Tag
Academia (2393)
Alliances (39883)
Alzheimer's disease (1277)
Approvals (16005)
Artificial intelligence (113)
Bankruptcy (302)
Best Places to Work (9442)
Biosimilars (78)
Biotechnology (93)
Breast cancer (96)
Cancer (884)
Career advice (2023)
Cell therapy (204)
Clinical research (57355)
Collaboration (299)
Compensation (157)
COVID-19 (2569)
Data (801)
Diabetes (137)
Diagnostics (5339)
Drug pricing (95)
Earnings (61408)
Employer resources (139)
Events (80710)
Executive appointments (213)
FDA (16530)
Funding (240)
Gene therapy (158)
GLP-1 (637)
Government (3957)
Healthcare (15607)
Infectious disease (2646)
Inflammatory bowel disease (97)
Interviews (453)
IPO (14632)
Job creations (3368)
Job search strategy (1697)
Layoffs (450)
Legal (7321)
Lung cancer (161)
Manufacturing (152)
Medical device (11596)
Medtech (11599)
Mergers & acquisitions (15287)
Metabolic disorders (393)
Neuroscience (1515)
NextGen Class of 2024 (5190)
Non-profit (3361)
Northern California (1094)
Obesity (238)
Opinion (201)
Patents (96)
People (45709)
Phase I (17104)
Phase II (24823)
Phase III (20091)
Pipeline (204)
Policy (77)
Postmarket research (2556)
Preclinical (7026)
Radiopharmaceuticals (215)
Rare diseases (185)
Real estate (4735)
Regulatory (21012)
Research institute (2137)
Resumes & cover letters (410)
Southern California (943)
Startups (2943)
United States (10196)
Vaccines (610)
Weight loss (202)
Date
Last 7 days (716)
Last 30 days (2561)
Last 365 days (32711)
2024 (27718)
2023 (36421)
2022 (47021)
2021 (50673)
2020 (47874)
2019 (38849)
2018 (29402)
2017 (29390)
2016 (27345)
2015 (29956)
2014 (23387)
2013 (19104)
2012 (20692)
2011 (21478)
2010 (19949)
Location
Africa (698)
Arizona (135)
Asia (34038)
Australia (5704)
California (2390)
Canada (922)
China (187)
Colorado (97)
Connecticut (120)
Europe (81475)
Florida (348)
Georgia (93)
Illinois (253)
Indiana (142)
Kansas (78)
Maryland (478)
Massachusetts (1965)
Michigan (113)
Minnesota (196)
New Jersey (755)
New York (731)
North Carolina (632)
Northern California (1094)
Ohio (101)
Pennsylvania (646)
South America (1085)
Southern California (943)
Texas (327)
Washington State (287)
559,014 Results for "abcheck s r o".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines.
January 3, 2024
·
2 min read
AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
AbCheck s.r.o. announced that it has entered into a collaboration with a biotech company developing antibodies targeting peripheral neural response, funded by a top-tier European Venture Capital firm.
February 21, 2023
·
2 min read
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
AbCheck s.r.o. announced that it has successfully completed the technology development activities specified under the terms of its research grant entitled “Research and development of a unique biotechnology for the isolation of antibodies with a therapeutic effect”.
March 9, 2023
·
2 min read
Ampersand Biomedicines Acquires AbCheck to Accelerate Platform and Product Development
Acquisition amplifies Ampersand’s in-house capabilities to generate AND-Body™ Therapeutics - programmed biologics across a broad range of diseases
January 3, 2024
·
3 min read
FDA
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.
June 26, 2024
·
17 min read
Business
Assertio Announces the Appointment of Brendan P. O’Grady as New CEO
Assertio Holdings, Inc. announced that its Board of Directors has appointed Brendan P. O’Grady, a highly accomplished pharmaceutical executive, as the Company’s new Chief Executive Officer and a member of the board, effective today, May 29, 2024.
May 29, 2024
·
4 min read
Genetown
bluebird bio Appoints O. James Sterling as Chief Financial Officer
bluebird bio, Inc. (Nasdaq: BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024.
May 29, 2024
·
7 min read
Business
Vivodyne Appoints Julie O’Shaughnessy as Chief Operating Officer
Vivodyne, a pioneering biotech company that grows and tests on lab-grown human tissues to accelerate therapeutics discovery and development, announced the appointment of Julie O’Shaughnessy as Chief Operating Officer.
May 7, 2024
·
3 min read
Business
Sensus Healthcare Announces Retirement of Director Samuel O’Rear
Sensus Healthcare, Inc. announces that Samuel O’Rear will not stand for reelection to the Company’s Board of Directors at the Company’s 2024 annual meeting of stockholders.
February 1, 2024
·
2 min read
Drug Development
Facing ‘Daunting’ Launch Schedule, Moderna to Slash $4B in R&D Spend by 2028
Analysts expressed skepticism about plans detailed by Moderna’s R&D chief Stephen Hoge to trim research spending in preparation for the launch of up to 10 new products.
September 13, 2024
·
4 min read
·
Annalee Armstrong
1 of 55,902
Next
